JP2020530470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530470A5 JP2020530470A5 JP2020507573A JP2020507573A JP2020530470A5 JP 2020530470 A5 JP2020530470 A5 JP 2020530470A5 JP 2020507573 A JP2020507573 A JP 2020507573A JP 2020507573 A JP2020507573 A JP 2020507573A JP 2020530470 A5 JP2020530470 A5 JP 2020530470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eye
- compound
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 20
- 210000001525 retina Anatomy 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 206010053648 Vascular occlusion Diseases 0.000 claims description 4
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims 8
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 238000002399 angioplasty Methods 0.000 claims 2
- 210000003161 choroid Anatomy 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 46
- 229940124130 Bcl inhibitor Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003412 degenerative effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 208000011325 dry age related macular degeneration Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 208000002691 Choroiditis Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 208000001351 Epiretinal Membrane Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 4
- 208000031471 Macular fibrosis Diseases 0.000 description 4
- 208000003971 Posterior uveitis Diseases 0.000 description 4
- 206010038848 Retinal detachment Diseases 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000000642 iatrogenic effect Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000004264 retinal detachment Effects 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000009327 senolytic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- 208000026726 vitreous disease Diseases 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940125381 senolytic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076763A JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/675,171 | 2017-08-11 | ||
| US15/675,171 US20180000816A1 (en) | 2015-02-06 | 2017-08-11 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US201762579793P | 2017-10-31 | 2017-10-31 | |
| US62/579,793 | 2017-10-31 | ||
| PCT/US2018/046553 WO2019033119A1 (en) | 2017-08-11 | 2018-08-13 | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076763A Division JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530470A JP2020530470A (ja) | 2020-10-22 |
| JP2020530470A5 true JP2020530470A5 (https=) | 2021-09-30 |
| JP7278257B2 JP7278257B2 (ja) | 2023-05-19 |
Family
ID=63254539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507573A Active JP7278257B2 (ja) | 2017-08-11 | 2018-08-13 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
| JP2023076763A Pending JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076763A Pending JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3441069B1 (https=) |
| JP (2) | JP7278257B2 (https=) |
| CN (1) | CN111372598A (https=) |
| AU (2) | AU2018314280B2 (https=) |
| CA (1) | CA3072673A1 (https=) |
| MX (2) | MX2020001644A (https=) |
| WO (1) | WO2019033119A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| KR20240014102A (ko) | 2018-06-29 | 2024-01-31 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
| CA3109432A1 (en) * | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| JP2022548071A (ja) * | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| US20230078120A1 (en) * | 2020-05-04 | 2023-03-16 | Ascentage Pharma (Suzhou) Co.,Ltd. | Methods for Treating Coronavirus Infections |
| JP2024501033A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物 |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| JP2024516367A (ja) * | 2021-04-13 | 2024-04-15 | ユニティ バイオテクノロジー インコーポレイテッド | 網膜血管症を治療する方法 |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| DE112024002866T5 (de) * | 2023-07-06 | 2026-04-23 | Jichi Medical University | Konzentrationsregulator für In-vivo-Substanzen oder Medikamente in einem halbgeschlossenen In-vivo-System |
| CN119925379B (zh) * | 2025-03-05 | 2025-09-05 | 中南大学湘雅医院 | Bcl3抑制剂在制备治疗青光眼的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| BR0208856B1 (pt) | 2001-04-11 | 2013-02-05 | processo para o tratamento de superfÍcie de uma junta com rosca e junta com rosca para tubos de aÇo. | |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
| SG192126A1 (en) | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| KR102318204B1 (ko) | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| CN105377289A (zh) * | 2013-04-21 | 2016-03-02 | 耶达研究及发展有限公司 | 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂 |
| US20150038140A1 (en) | 2013-07-31 | 2015-02-05 | Qualcomm Incorporated | Predictive mobility in cellular networks |
| WO2015017536A1 (en) | 2013-07-31 | 2015-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for evaluating progression of age-related macular degeneration |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| US11111259B2 (en) * | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
-
2018
- 2018-08-13 EP EP18188799.3A patent/EP3441069B1/en active Active
- 2018-08-13 CA CA3072673A patent/CA3072673A1/en active Pending
- 2018-08-13 AU AU2018314280A patent/AU2018314280B2/en active Active
- 2018-08-13 EP EP23166363.4A patent/EP4234025A3/en active Pending
- 2018-08-13 JP JP2020507573A patent/JP7278257B2/ja active Active
- 2018-08-13 MX MX2020001644A patent/MX2020001644A/es unknown
- 2018-08-13 WO PCT/US2018/046553 patent/WO2019033119A1/en not_active Ceased
- 2018-08-13 CN CN201880063962.8A patent/CN111372598A/zh active Pending
-
2020
- 2020-02-10 MX MX2025004366A patent/MX2025004366A/es unknown
-
2023
- 2023-05-08 JP JP2023076763A patent/JP2023100864A/ja active Pending
- 2023-10-16 AU AU2023251388A patent/AU2023251388B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530470A5 (https=) | ||
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| US20110117189A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| US11129838B2 (en) | Methods of inhibiting pathological angiogenesis | |
| CN109996814B (zh) | 多激酶抑制剂及在眼部纤维化中的用途 | |
| TWI629985B (zh) | 眼底疾患治療劑 | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| WO2008124828A1 (en) | Methods for treating vascular disruption disorders | |
| US20230025836A1 (en) | Eye drop composition for preventing or treating eye disease | |
| JPWO2002000260A1 (ja) | 視神経疾患等治療剤 | |
| JP4150846B2 (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| RU2024106207A (ru) | Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки | |
| CN113768929B (zh) | Fdi化合物在眼科疾病中的用途 | |
| WO2002078713A1 (fr) | Medicaments contre les affections retiniennes et choroidiennes contenant des steroides comme principe actif | |
| EP2875811A1 (en) | Use of dobesilate for treating ocular haemorrhages | |
| WO2026078034A1 (en) | Sitagliptin for use in retinal diseases with neovascularization | |
| HK1214526B (zh) | 眼底疾病治疗剂 |